Drug manufacturer Eli Lilly said it is pleased with a court's injunction yesterday stopping 340B dispute resolution proceedings against it over its denials of 340B pricing on contract pharmacy drugs. | Shutterstock

Injunction in Lilly Case Could Cause HHS to Re-Issue 340B Dispute Resolution Rule

A federal judge’s decision to temporarily shield drug manufacturer Eli Lilly from the 340B program’s administrative dispute resolution (ADR) process could cause the government to issue 340B ADR regulations all over again, health care attorneys say.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content